In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period

• Ngā kaituhi matua: Minji Tak (Author), Hawon Jeong (Author), Jihoon Yun (Author), Jihyun Kim (Author), Soyeon Kim (Author), Yoonsook Lee (Author), Su Jin Park (Author)
• Hōputu: Pukapuka
• I whakaputaina: Adis, Springer Healthcare, 2023-08-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Abstract Introduction SB12 is a biosimilar to eculizumab reference product [SolirisTM (Soliris is a trademark of Alexion Pharmaceuticals, Inc.)] that acts as a C5 complement protein inhibitor. The infusion stability of in-use (diluted) SB12 outside the conditions stated in the reference product'...